<p><strong>Adult (Intravenous)</strong>: Initially, 3.7 mg/m2, increase dose wkly based on WBC counts in increments of about 1.8 mg/m2&nbsp;until leukocyte count decreases to about 3000/mm3, or max wkly dose of 18.5 mg/m2&nbsp;reached. Do not increase dose if leukocyte count is reduced to approximately 3000 cells/mm3; administer the max dose that does not cause leucopenia for maintenance. Do not increase subsequent doses if onolytic activity occurs before leucopenic effect. Usual dose: 5.5-7.4 mg/m2&nbsp;per wk. Do not admin next dose, even though 7 days have lapsed unless the leukocyte count has returned to at least 4000/mm3.<br />
<br />
<strong>Child (Intravenous)</strong>: Initial 2.5 mg/m2&nbsp;of BSA, increased dose at wkly intervals in increments of about 1.25 mg/m2&nbsp;until leukocyte count decreases to about 3000/ mm3, or max wkly dose of 12.5 mg/m2&nbsp;reached. Do not increase dose once leukocyte count reaches approximately 3000 cells/mm3, instead, a dose of 1 increment smaller to be admin at wkly intervals for maintenance i.e. patient receives the max dose that does not cause leucopenia. If onolytic activity is encountered before leucopenic effect, then there is no need to increase subsequent doses. Do not admin next dose, even though 7 days have lapsed unless the leukocyte count has returned to at least 4000/mm3. Duration of maintenance therapy depends on disease state and the antineoplastic agent combination.</p>